Almirall SA
ALM
ISIN ES0157097017 / Valor 3180354
Almirall SA
UMushroom community rating:
About company
Almirall SA is a Barcelona-based global pharmaceutical company that focuses on skin health, partnering with healthcare professionals to provide medical solutions for patients. The company's efforts are concentrated on combating skin health diseases and enhancing the well-being of individuals. Almirall has a diverse portfolio of products, including treatments for acne, dermatoses, nail diseases, onychomycosis, nail psoriasis, nail dystrophy, skin mycosis, rosacea, and COPD. Additionally, the company has engaged in strategic acquisitions and partnerships to expand its offerings and reach in the pharmaceutical industry.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (10.01.2025):
Revenue Growth
Almirall SA reported its full-year 2023 financial results, highlighting a 4% year-on-year growth in net sales, reaching €894.5 million. This growth was primarily driven by the strong performance of its European Dermatology business, with key products like Ilumetri®, Klisyri®, and Wynzora® showing significant sales increases.
EBITDA and Profit
The company's total EBITDA for 2023 was €174.1 million, representing a 12.2% decrease compared to the previous year. This decline was attributed to reduced contributions from other income sources, such as the AstraZeneca/Covis milestones, and increased investments in product launches and expansions.
Net Income
Almirall SA reported a normalized net income of €15.6 million for 2023, a 53.4% decrease from the previous year. The company also recorded a net loss of €38.5 million, primarily due to impairment charges related to the carrying value of the intangible asset for Seysara®.
Research and Development
In 2023, Almirall SA invested €111 million in research and development, accounting for 12% of its net sales. This investment supported the development and launch of new products, including the successful introduction of EBGLYSS® in Germany and the planned rollout in other European countries in 2024 and 2025.
2024 Outlook
Looking ahead to 2024, Almirall SA anticipates a high single-digit growth in net sales and expects total EBITDA to be between €175 million and €190 million. The company plans to continue expanding its dermatology portfolio and exploring external opportunities for early and mid-stage assets to drive future growth.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1811 M
Market cap (USD)
284,689
Daily traded volume (Shares)
8.14 / 8.03
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
